Dartmouth-Hitchcock
Lebanon, New Hampshire, 03756, United States
NCT Number: NCT07735715
The goal of this clinical trial is to learn more about the home-based epilepsy self-management program, HOBSCOTCH, for improving cognitive function (thinking and memory) and quality of life specifically in young adults, ages 18 - 29 years, who have epilepsy. It will also learn if a modification of the program for youth with epilepsy, ages 13 - 17, improves thinking and memory and quality of life and reduces stress for their parents.
Researchers will enroll 260 young adults with epilepsy and 40 youth with epilepsy and their parent or guardian. Researchers will compare responses to questionnaires and surveys before and after participation in the HOBSCOTCH program to see if thinking, memory and quality of life have improved for young adults and youth with epilepsy and to see if parents have improved quality of life as well.
Participants will:
* Attend 9 weekly one-hour sessions of the HOBSCOTH program in their homes with a one-on-one coach using their computer or their phone; youth with epilepsy (ages 13 - 17) will attend alongside a parent or legal guardian. * Keep a short daily diary about their seizures and activity in the program using a smart phone app(lication) * Complete surveys and questionnaires before HOBSCOTCH and 3 months and 6 months later.
There are no study visits to a medical center. HOBSCOTCH is a virtual or telehealth intervention.
Trial opening soon.
Get Notified13 year–29 year
All sexes
Interventional
Not applicable
Lebanon, New Hampshire, 03756, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Inclusion criteria
for Parent of Youth with Epilepsy (YWE):
Exclusion criteria
HOBSCOTCH (HOme Based Self-Management and COgnitive Training CHanges Lives) is a home-based self-management program to treat cognitive symptoms and improve quality of life, while minimizing the barriers of access to care, for people with epilepsy and other neurological disorders. The program is based on Problem Solving Therapy (PST) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life. HOBSCOTCH-YOUTH is an adaptation of the HOBSCOTCH program for youth ages 13 - 17 who have epilepsy.
Time frame: Baseline, 3 months and 6 months post HOBSCOTCH intervention
The QOLIE-10 (Quality of Life in Epilepsy Inventory-10) is a validated 10-item, patient-reported questionnaire designed to assess health-related quality of life in adults and adolescents with epilepsy, focusing on core aspects such as seizure worries, daily activities, mood, energy, and medication effects. Numerical responses are summed and divided by the total number of items answered with lower scores reflecting better quality of life or fewer perceived difficulties.
Time frame: Baseline, 3 months and 6 months post HOBSCOTCH intervention
The Cognitive Function sub-scale of the NeuroQOL is a brief validated tool developed by the NIH for use in patients with neurological disease. Scores range from 8 to 40, with a higher score indicating better reported cognitive functioning.
Time frame: Baseline, 3 months and 6 months post HOBSCOTCH-YOUTH intervention
The Quality of Life in Epilepsy Inventory for Adolescents (QOLIE-AD-48) is a validated instrument designed to measure health-related quality of life (HRQOL) in adolescents aged 11-18 years with epilepsy. It consists of 8 domains and is scored based on a 5-point Likert scale response from 1 - 5 (very poor - excellent). Higher scores reflect better functioning or quality of life.
Time frame: Baseline, 3 months and 6 months post-HOBSCOTCH-YOUTH intervention
The Zarit Burden Interview is a 22-item questionnaire designed to measure the extent to which a caregiver perceives his or her level of burden as a result of caring for a person with a particular diagnosis. A 5-point Likert scale is used with a higher score indicating a greater level of perceived burden.
Time frame: Baseline, 3 months and 6 months post HOBSCOTCH intervention
The AESMMI-65 is a 65-item validated scale that assesses use of epilepsy self-management practices. Scores range from 65 to 325, with a higher score indicating more frequent use of self-management strategies.
Time frame: Baseline, 3 months and 6 months post HOBSCOTCH intervention
The EMQ-R is a validated self-administered, subjective measure designed to assess memory in everyday life. It consists of 13 items scored on a 5-point Likert scale from 0 - 4 with total scores ranging from 0 - 52. Higher scores indicate a greater frequency of self-reported everyday memory failures.
Time frame: Baseline, 3 months and 6 months post HOBSCOTCH intervention
The Epilepsy Self-Stigma Scale is an eight-item self-report questionnaire designed to measure the extent to which people with epilepsy internalize negative societal attitudes toward their condition. Each item is rated on a 5-point (0- 4) Likert scale and summed with higher scores and a higher sum indicating higher perceived self-stigma.
Time frame: Baseline, 3 months and 6 months post HOBSCOTCH intervention
The PHQ-8 is a validated self-report, eight-item questionnaire measuring depressive symptom frequency over the past two weeks using a 4-point Likert scale. Scores are summed with higher scores indicating poorer mood and greater self-report of depression.
Time frame: Baseline, 3 months and 6 months post HOBSCOTCH intervention
The Brief Epilepsy Anxiety Survey Instrument (brEASI) is an 8 item, self-administered, validated questionnaire designed to screen for anxiety disorders in people with epilepsy. It consists of 8 items scored on a 4-point Likert scale (0 - 3) with higher scores and a higher sum of all scores indicating greater degrees of anxiety.
Time frame: Baseline, 3 months and 6 months post HOBSCOTCH intervention
The Personal Impact of Epilepsy Scale (PIES) is a validated 25-item self-reported questionnaire developed to measure the overall impact of epilepsy on a person's life, with specific focus on seizures, medication side effects, comorbidities, and overall quality of life (QOL). Items are scored using a 5-point Likert scale (0 - 4) with higher scores and a higher total sum indicating a greater perceived negative personal impact of epilepsy.
Time frame: Baseline, 3 months and 6 months post HOBSCOTCH-YOUTH intervention
The BRIEF-SR is a standardized self-report of executive functioning designed for ages 11 to 18 years measuring an adolescent's perspective on cognitive, emotional, and behavioral self-regulation in everyday life. It consists of 80 items rated by the adolescent using a 3-point Likert scale (1-never, 2-sometimes, 3-often). Raw scores are summed and converted to a T score (50/10) with a higher score indicating greater difficulty in executive functioning.
Time frame: Baseline, 3 months and 6 months post-HOBSCOTCH-YOUTH intervention
The Behavior Rating Inventory of Executive Function - Parent Form (BRIEF-Parent) is a self-report questionnaire completed by a parent or guardian to assess executive function in their child. It contains 86 items scored by the parent using a 3-point Likert scale (1-Never, 2-Sometimes, 3-Often). Raw scores are summed and converted to a T-Score (50/10) with higher scores indicating greater perceived difficulties with executive function.
Time frame: Baseline, 3 months and 6 months post-HOBSCOTCH-YOUTH intervention
The Affiliate Stigma Scale is a validated instrument designed to measure the extent of self-stigmatization experienced by associates (e.g., family members, caregivers) of someone with a stigmatized disability. It contains 22 items using a 4-point Likert scale (1 - 4) with higher scores and total scores indicating a greater degree of perceived self-stigma.
Time frame: Recorded daily and compared between baseline and 3 months-post HOBSCOTCH/HOBSCOTCH-YOUTH intervention
YAWE and YWE will self-report their seizure activity, Yes or No, using a smartphone app(lication). The smart phone app was developed by the HOBSCOTH Institute at Dartmouth and is used clinically in the HOBSCOTCH program.
Time frame: Recorded daily and compared between baseline and 3 months-post HOBSCOTCH/HOBSCOTCH-YOUTH intervention
YAWE and YWE will self-report their medication adherence activity, Yes or No, using a smartphone app(lication). The smart phone app was developed by the HOBSCOTH Institute at Dartmouth and is used clinically in the HOBSCOTCH program.
Time frame: Recorded daily and compared between baseline and 3 months-post HOBSCOTCH/HOBSCOTCH-YOUTH intervention
YAWE and YWE will self-report their use of memory strategies, Yes or No, using a smartphone app(lication). The smart phone app was developed by the HOBSCOTH Institute at Dartmouth and is used clinically in the HOBSCOTCH program.
Time frame: Recorded daily and compared between baseline and 3 months-post HOBSCOTCH/HOBSCOTCH-YOUTH intervention
YAWE and YWE will give self-reports of well-being on a 5-point Likert scale (Great, Good, Average, Poor, Very Poor) using a smartphone app(lication). The smart phone app was developed by the HOBSCOTH Institute at Dartmouth and is used clinically in the HOBSCOTCH program.
Time frame: At 3 months, i.e. after completing the HOBSCOTCH or HOBSCOTCH-YOUTH intervention
The Participant Satisfaction Survey was developed through the original HOBSCOTH program and is used in clinical practice for quality improvement. It has been modified to address YAWE, YWE and Parent's satisfaction as a result or participating in this study and contains 9 items scored on a 5- point Likert scale with a higher score indicating greater satisfaction with the program. There is also an open-ended portion to give additional feedback.
Time frame: 3 months, i.e. after completing the HOBSCOTCH intervention
CollaboRATE is a brief, 3 item patient-reported measure of shared decision making, namely the perception of being informed and then involved in decision-making steps. A 10-point anchor scale from 0 (no effort was made) to 9 (every effort was made) with higher scores representing a greater perception of a shared decision-making effort.
Time frame: 3 months, i.e. after completing the HOBSCOTCH-YOUTH intervention
CollaboRATE-parent is a brief, 3 item parent-reported measure of shared decision making, namely the perception of being informed and then involved in decision-making steps for their child. A 10-point anchor scale from 0 (no effort was made) to 9 (every effort was made) with higher scores representing a greater perception of a shared decision-making effort
Time frame: Week 1 through Week 8 of HOBSCOTCH/HOBSCOTCH-YOUTH intervention
Homework assignments are given each week in which participants are asked to think about solutions using the Problem Solving Therapy taught in the program. Compliance is measured by Yes (completed homework assignment) or No (did not complete homework assignment).
Time frame: 3 months and 6 months post HOBSCOTCH intervention
Time frame: 3 months and 6 months post HOBSCOTCH intervention
Time frame: 3 months and 6 months post HOBSOTCH-YOUTH intervention
(Quality of Life in Epilepsy Inventory - Adolescents - 48)
Time frame: 3 months and 6 months post HOBSCOTCH-YOUTH intervention
Contact information is provided by the study sponsor or research team.
Trina K Dawson, BA
CONTACT
Wren M Kaden, BA
CONTACT
Dartmouth-Hitchcock Medical Center
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07228338
Brain Diseases, Central Nervous System Diseases
Dallas, Texas, United States
View Trial DetailsNCT05594017
Brain Diseases, Central Nervous System Diseases
Dallas, Texas, United States
View Trial DetailsNCT06754124
Behavior, Behavioral Symptoms
Rize, Güneysu, Turkey (Türkiye)
View Trial DetailsNCT06143241
Brain Diseases, Central Nervous System Diseases
Izmir, Bornova, Turkey (Türkiye)
View Trial Details